IP62: Prostate Cancer: Markers I
Sunday, May 17, 2026 1:00 PM to 3:00 PM · 2 hr. (America/New_York)
146A
Poster and Podium Sessions
Oncology: Prostate
Sunday, May 17
IP62-02: Biomarkers of response to prostate cancer vaccine and immune checkpoint inhibition: Synergistic regulation of soluble CD137 and IL-15
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-03: Prostate Subtyping Classifier Predicts Prostate Cancer Specific Mortality after Radical Prostatectomy: Moving Beyond Decipher
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-04: 4K Density: Adjusting the 4Kscore for Prostate Volume to Improve Risk Stratification of Clinically Significant Prostate Cancer in Men Undergoing Prostate Biopsy
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
Timothy Guerard · University of Miami
IP62-05: Correlative analysis of the expression of two PET imaging targets, PSMA and ACP3, in large RP cohort from the Decipher GRID registry
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-06: Prognostic Implications of Very High Decipher Scores in Prostate Cancer: Toward a Refined Genomic Risk Classification
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-07: Low-Apparent Diffusion Coefficient Lesion Volume and Whole-body PSA Density as Prognostic Biomarkers in Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-08: Cachexia Index, Allostatic Load, and Body Composition Phenotypes in Metastatic Prostate Cancer
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-09: External Validation of a Post-Radical Prostatectomy Multimodal Artificial Intelligence Model for Predicting Oncologic Outcomes After Surgery
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-10: Targeting PLXND1 using RNA bioengineering technologies and customized lipid nanoparticles in advanced prostate cancer
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-11: Can PSMA PET/CT be used for patients selection in B7-H3-targeted therapy?: Exploration and validation based on bioinformatics, IHC, and molecular imaging
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
Yang Luo
IP62-12: Post Prostatectomy Genomic Analysis for Predicting Prostate Cancer Disease Specific Mortality
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-13: Molecular characterization of the ductal histological type of prostate cancer
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
Ana Carolina Bogoevich
IP62-14: Can MRI-Derived Imaging Features Predict Biological Aging of the Prostate and Its Association with csPCa?
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-15: Clinical utility of biomarkers for detecting significant prostate cancer in PI-RADS 3 lesions
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-16: Prognostic significance of HSP90AB1 expression in prostate cancer: Molecular associations and clinical implications
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-17: Urinary Exosomal FAM153C-RPL19 Drives Accurate Detection and Risk Stratification of Prostate Cancer: A Multicentre Chinese Cohort Study
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-18: Organic Electrochemical Transistor with Self-Assembled Coronene Nanostructures as an Extracellular Vesicle-Based Liquid Biopsy Platform for miRNA and PSA Detection in Prostate Cancer
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-19: Early ultrasensitive prostate specific antigen predicts risk of salvage therapy or biochemical recurrence after radical prostatectomy
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-21: Delineating the Evolutionary Trajectory of Therapy Resistance in Prostate Cancer via Single-Cell Reconstruction to Develop and Validate a Clinically Actionable Cell-State Transition Signature
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-22: Genomic Classifier Results and Use of Post-Prostatectomy Treatment Among a National Cohortof Patients with Prostate Cancer
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-23: Influence of Radiology and Genomics on Extreme Reclassification During Surveillance
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-24: Predictive value of HSD3B1 germline single nucleotide polymorphism rs1047303 for hormone therapy outcomes in Chinese prostate cancer patients
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-25: Early Prediction of Response to ADT Plus ARPIs in mHSPC Using Interpretable Machine Learning on PSMA PET/CT: A Real-World Study
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
Yinzhao Wang
IP62-26: Rapid Test for the Detection of Prostate Cancer
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
IP62-27: Innovative Preclinical Models For Precision Medicine In Advanced Prostate Cancer: Preliminary Results From The INSIDE Study
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
Sabrina De Cillis
IP62-28: From DNA to Decision: The Synergy of Germline and Somatic Testing in Prostate Cancer
Sunday, May 17, 2026 1:00 PM to 3:00 PM
146A
Shumei Kato